Andere Sprachen ABVC BioPharma, Inc.

Aktien

A3EQ35

US00091F3047

ABVC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
0.9901 ^USD	-5.70%		-9.17%	-14.65%

10.04.	ABVC BioPharma, Inc., BioLite, Inc. und Rgene Corporation schließen Term Sheet mit OncoX BioPharma, Inc. ab	CI
26.03.	ABVC BioPharma, Inc. und BioFirst Corporation schließen globales Lizenzabkommen mit ForSeeCon Eye Corporation	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share	18.04.
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	17.04.
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M	10.04.
ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	10.04.
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M	26.03.
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	26.03.
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars	21.03.
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine	19.03.
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update	14.03.
ABVC BioPharma : Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - Form 8-K	14.03.
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13.03.
ABVC BioPharma Signs Licensing Deal With Senior Paradise	15.02.
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues	15.02.
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue	15.02.
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)	12.02.
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share	08.02.
ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC	17.01.
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	08.01.
Top Premarket Decliners	04.01.
Sector Update: Health Care Stocks Mixed Late Afternoon	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ABVC BioPharma, Inc.

Aktien

A3EQ35

US00091F3047

ABVC

Andere Sprachen

Filter